| Literature DB >> 33135383 |
Lisa Nalbach1, Leticia P Roma2, Beate M Schmitt1, Vivien Becker1, Christina Körbel1, Selina Wrublewsky1, Mandy Pack1, Thomas Später1, Wolfgang Metzger3, Maximilian M Menger1,4, Florian S Frueh5, Claudia Götz6, Haopeng Lin7, Joseline E Manning Fox7, Patrick E MacDonald7, Michael D Menger1, Matthias W Laschke1, Emmanuel Ampofo1.
Abstract
Pancreatic islet transplantation still represents a promising therapeutic strategy for curative treatment of type 1 diabetes mellitus. However, a limited number of organ donors and insufficient vascularization with islet engraftment failure restrict the successful transfer of this approach into clinical practice. To overcome these problems, we herein introduce a novel strategy for the generation of prevascularized islet organoids by the fusion of pancreatic islet cells with functional native microvessels. These insulin-secreting organoids exhibit a significantly higher angiogenic activity compared to freshly isolated islets, cultured islets, and non-prevascularized islet organoids. This is caused by paracrine signaling between the β-cells and the microvessels, mediated by insulin binding to its corresponding receptor on endothelial cells. In vivo, the prevascularized islet organoids are rapidly blood-perfused after transplantation by the interconnection of their autochthonous microvasculature with surrounding blood vessels. As a consequence, a lower number of islet grafts are required to restore normoglycemia in diabetic mice. Thus, prevascularized islet organoids may be used to improve the success rates of clinical islet transplantation.Entities:
Keywords: diabetes; insulin; islet transplantation; microvascular fragments; vascularization
Mesh:
Substances:
Year: 2020 PMID: 33135383 PMCID: PMC7799357 DOI: 10.15252/emmm.202012616
Source DB: PubMed Journal: EMBO Mol Med ISSN: 1757-4676 Impact factor: 14.260